期刊档案
Current Controlled Trials in Cardiovascular Medicine
ISSN 1468-6708 · eISSN 1468-6694 · BMC · United Kingdom
Current Controlled Trials in Cardiovascular Medicine 完全开放获取，APC 约 2,890 美元，投稿社区反馈审稿约 10 周，2025 年发文 0 篇。
研究范围
研究范围与定位
Current Controlled Trials in Cardiovascular Medicine 由 BMC 出版。按 OpenAlex 近年发文统计，该刊主要发表 Acute Myocardial Infarction Research、Lipoproteins and Cardiovascular Health、Coronary Interventions and Diagnostics 等主题的论文，这 3 个主题约占 24.5%，主导子领域为 Cardiology and Cardiovascular Medicine。（根据 OpenAlex 主题统计与中科院分区数据生成）
Trials encompasses all aspects of the performance and findings of randomized controlled trials in human health. We publish articles on general trial methodology and research into trial processes, as well as study protocols and statistical analysis plans for randomised controlled trials, commentaries and traditional results papers - regardless of outcome or significance of findings. Our aim is to promote transparency in the reporting of randomised trials and build an evidence base that will help inform the design and reporting of future trials. Within this remit, we consider articles or study protocols assessing aspects of the design, conduct or reporting of trials, as well as assessment and evaluation of lessons learnt from past trials, including those that were prematurely ended. We advocate for the collective success for trials and the importance of linking publications together (the thread of evidence). To facilitate complete and transparency reporting of research, Trials does not ask authors to adhere to strict word limits. We request that authors provide the detail required to make the research replicable. We ask that authors communicate not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide. Trials aims to experiment with, and refine, innovative approaches to improving communication about randomized controlled trials. We are keen to move beyond publishing traditional trial results articles (although these are included), and we believe this journal represents an exciting opportunity to advance the science and reporting of trials.
摘自期刊官网 Aims & Scope
主编 Thomas Braun出版商官网
编委会国家分布：中国大陆 32 位（约 11%）；主要国家 英国 84、美国 50、中国 32、印度 18、加拿大 16（共 300 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Acute Myocardial Infarction ResearchMedicine9.2%
- Lipoproteins and Cardiovascular HealthMedicine8%
- Coronary Interventions and DiagnosticsMedicine7.4%
- Cardiac Imaging and DiagnosticsMedicine7.4%
- Blood Pressure and Hypertension StudiesMedicine6.8%
- Statistical Methods in Clinical TrialsMathematics6.8%
- Cardiovascular Function and Risk FactorsMedicine4.3%
- Heart Failure Treatment and ManagementMedicine3.7%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
数据库收录
DOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- h-index
- 23OpenAlex ·
- i10-index
- 36OpenAlex ·
- 两年平均被引
- 0OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 90 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 0 | 0 | 24 |
| 2025 | 0 | 0 | 31 |
| 2024 | 0 | 0 | 47 |
| 2023 | 0 | 0 | 61 |
| 2022 | 0 | 0 | 53 |
| 2021 | 0 | 0 | 60 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
- 平均审稿速度（社区反馈）
- 10 WeeksLetPub ·
- 投稿到发表（期刊自报）
- 约 10 周DOAJ ·
- 评审方式
- 开放同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | EUR 2,490 / USD 2,890 / GBP 2,190 | 有 | CC BY | |
| OpenAlex | GBP 1,370 | — | — | |
| LetPub | GBP 1,370 | 有 | — | |
| 出版商官网 | GBP 2,190 / USD 2,890 / EUR 2,490 / GBP 1,205 / USD 1,735 / EUR 1,420 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点1 项，摘自作者指南
- 推荐审稿人
- 可选
接收的文章类型7 种
- commentResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- editorialResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- methodology reviewResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- researchResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- reviewResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- study protocolResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
- updateResearch Methodology Review Study protocol Comment Editorial Update未说明篇幅
官网政策摘录数据可用性、许可与版权、开放获取、同行评审、查重
- 数据可用性 Formatting the 'Availability of data and materials' section of your manuscript
稿件需包含'数据与材料可用性'声明，说明支持结论的数据集是否公开可用。 模型中文摘要
The following format for the 'Availability of data and materials section of your manuscript should be used:
原文 ↗出版商官网 ·- 许可与版权 Licensing and copyright
开放获取文章在Springer Nature期刊中依据Creative Commons许可发布，作者保留文章版权；Trials文章以CC BY-NC-ND 4.0或CC BY 4.0许可发布。 模型中文摘要
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Trials articles are published open access under a CC BY-NC-ND (Creative Commons Attribution Non-Commercial N…
原文 ↗出版商官网 ·- 开放获取 Benefits of open access
开放获取（OA）带来更多引用、下载与影响力，并有助于遵守许多国际主要资助者政策。 模型中文摘要
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
原文 ↗出版商官网 ·- 同行评审 Peer review policy
同行评审由相关领域独立研究者评估稿件，通常基于科学稳健性、原创性和清晰度三项标准，反馈指导编辑的发表决定。 模型中文摘要
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
原文 ↗出版商官网 ·- 查重
请访问BioMed Central网站阅读完整的编辑政策。 模型中文摘要
Visit the BioMed Central website to read our full editorial policies.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- BMC
- 出版国家或地区
- United Kingdom
- 出版语言
- English
- ISSN
- 1468-6708
- 电子版 ISSN
- 1468-6694
- 官方链接
- 期刊主页 ↗OpenAlex
- 投稿系统 ↗出版商官网
- 作者指南 ↗LetPub
- Aims & Scope ↗LetPub
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗LetPub
- 编委会 ↗LetPub
- 查重政策 ↗DOAJ
常见问题
关于 Current Controlled Trials in Cardiovascular Medicine 的常见问题
Current Controlled Trials in Cardiovascular Medicine 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 10 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Current Controlled Trials in Cardiovascular Medicine 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 300 位编委中，中国大陆 32 位（约 11%）；人数最多的国家是 英国（84 位）、美国（50 位）、中国（32 位）。统计按编委会页面列出的机构国家计，仅供参考。
Current Controlled Trials in Cardiovascular Medicine 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Current Controlled Trials in Cardiovascular Medicine 被 DOAJ 收录。
Current Controlled Trials in Cardiovascular Medicine 是开放获取期刊吗？版面费多少？
Current Controlled Trials in Cardiovascular Medicine 为完全开放获取。APC 约 2,890 美元。
来源与更新
本页事实来自 LetPub、OpenAlex、DOAJ、出版商官网；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。